BioCryst Boosts Revenue Guidance on ORLADEYO Growth and Pipeline Progress
Event summary
- BioCryst reported Q2 2026 revenue of $218.3M, up 34% YoY, with ORLADEYO contributing $158.2M (+1% YoY).
- Company raised full-year total revenue guidance to $690M–$715M (previously $635M–$660M) but maintained ORLADEYO revenue outlook at $625M–$645M.
- Began shipping ORLADEYO oral pellets for pediatric HAE patients on August 3, with strong initial prescription demand (47 YTD).
- Completed enrollment in ALPHA-ORBIT pivotal study of navenibart; top-line results expected Q3 2027.
The big picture
BioCryst's strategic pivot toward external pipeline development aligns with broader biotech trends favoring focused capital allocation. The revenue guidance increase reflects confidence in ORLADEYO's commercialization, but the company's ability to deliver on navenibart's potential will be critical for long-term growth.
What we're watching
- Commercial Momentum
- Whether BioCryst can sustain ORLADEYO's growth trajectory amid pediatric expansion and CareMed partnership transition.
- Pipeline Execution
- The pace at which navenibart and BCX17725 advance toward clinical milestones, particularly with ALPHA-ORBIT results due in 2027.
- Cost Discipline
- How effectively BioCryst executes its shift to external innovation, including the closure of internal R&D programs and Birmingham facility.
Related topics